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ABSTRACT
Introduction: Harmonizing data across cohorts is
important for validating findings or combining data in
meta-analyses. We replicate and validate a previous
conversion of MoCA to MMSE in PD.
Methods: We used five studies with 1,161 PD individu-
als and 2,091 observations measured with both the
MoCA and MMSE. We compared a previously pub-
lished conversion table using equipercentile equating
with log-linear smoothing to our internally derived
scores.
Results: Both conversions found good agreement
within and across the studies when comparing true
and converted MMSE (mean difference: 0.05; standard
deviation: 1.84; median difference: 0; interquartile
range: –1 to 1, using internal conversion).
Conclusions: These results show that one can get a
reliable and valid conversion between two commonly
used measures of cognition in PD studies. These
approaches need to be applied to other scales and
domains to enable large-scale collaborative analyses
across multiple PD cohorts. VC 2016 International Par-
kinson and Movement Disorder Society
Key Words: Parkinson’s disease, Mini–Mental State
Examination, Montreal Cognitive Assessment, equating
There are many studies of individuals with Parkin-
son’s disease (PD), although often data are limited by
selected samples and small sample sizes meaning that
analyses are underpowered. Researchers often seek to
validate previous research in a new data set or com-
bine data in a meta-analysis, but comparing and pool-
ing findings may be problematic if different measures
have been used. A common nonmotor feature of PD is
cognitive impairment, and two of the most popular
screening tools are the Mini–Mental State Examina-
tion (MMSE)1 and the Montreal Cognitive Assessment
(MoCA).2 There are well-established methods for scale
conversion3 and a previous study4 has applied these to
convert the MoCA to the MMSE in patients with PD.
The validity of this conversion has been evaluated in a
small sample of 139 subjects with PD, with a narrow
distribution of MoCA scores, which suggested it was
reasonably good.5 We present both a replication of
the methods of van Steenoven and colleagues and a
validation of their conversion chart in a much larger
independent sample including individuals with a wider
range of MoCA and MMSE scores.
Patients and Methods
Study Population
We used data from five studies that are a part of the
Joint Programme Neurodegenerative Disease (JPND)
consortium who have data collected on both the
MMSE and MoCA in patients with PD. In all cases,
the MoCA scores were adjusted by adding 1 point (to
a maximum of 30) for all those with 12 years or less
of education. Brief details are provided below.
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The MODEP cohort consists of incident PD (n 5
22), prevalent PD (n 5 18), and controls (n 5 24)
with up to 8 visits.6 We restricted this analysis to the
incident and prevalent PD arms. The ABC-PD study is
an ongoing cross-sectional study of PD with 91 indi-
viduals included in this analysis. The De Novo Parkin-
son (DeNoPa) study is an untreated incidence PD
cohort (n 5 159) with a control arm (n 5 110).7,8
This cohort has data at baseline and on one follow-up
visit. We included 123 PD patients after excluding
individuals who were found to have other neurological
diseases at follow-up. The EPIPARK cohort has 112
PD patients and 543 controls with data on up to three
visits.9 We restricted this analysis to the PD patients.
The Oxford Discovery cohort has data on 958 PD
patients, 293 controls, and 180 at risk of PD (as of
January 2015)10 with data on up to three visits per
individual. We included only the 795 PD patients who
were recently diagnosed (within 3.5 years) and with
clinical probability of PD 90%.
The analyzed data included only the PD subjects for
direct comparison with the original van Steenoven and
colleagues article.4 In studies where longitudinal data
were available, we used data from every visit.
Ethics
MODEP received ethical approval no. 46/2010BO1
of the Medical Ethical Board of the University of Tue-
bingen. ABC-PD received ethical approval no. 686/
2013BO1 of the Medical Ethical Board of the Univer-
sity of Tuebingen. For DeNoPa, institutional review
board approval was obtained from the Ethikkommis-
sion der Hessischen Landes€arztekammer in Fankfurt,
Germany (FF89/2008) on 26 March 2009. EPIPARK
received ethical approval no. 09-069. Oxford Discov-
ery received ethical approval reference no. 10/H0505/
71 from the NRES committee, South Central, Berk-
shire Ethics Committee.
Statistical Analysis
To convert MoCA score to MMSE score, we used
exactly the same equipercentile method with log-linear
smoothing that is described in the van Steenoven and
colleagues article4 (see another work3 for methodolog-
ical details). This method matches scores on the two
tests by their percentile ranks after smoothing the dis-
tribution. The analysis was performed in the R statisti-
cal software (R Foundation for Statistical Computing),
using the equate library.11 We then validated our
MoCA to MMSE conversion and the proposed MoCA
to MMSE conversion from the van Steenoven and
colleagues article within each of our five cohorts and
also across the five cohorts. This was carried out by
calculating the difference (delta) between the true and
equivalent MMSE and reporting the mean, standard
deviation (SD), median, and interquartile range (IQR)
of this delta along with the root mean squared error
(RMSE). Smaller (in terms of absolute value) mean,
SD, median, IQR, and RMSE denotes a more accurate
conversion from MOCA to MMSE. We also calcu-
lated the intraclass correlation and the percentage of
observations which were within 62 points of the true
and equivalent MMSE to enable comparison with a
previous validation.5
Results
We analyzed data from 1,161 individuals contribut-
ing 1,112 observations at baseline and 979 observa-
tions at follow-up visits. (MODEP: 40 individuals
with 39 observations at baseline, 40 at the second
visit, 32 at the third and fourth visits, 25 at the fifth
visit, 22 at the sixth visit, 26 at the seventh visit, and
20 at the eighth visit, giving 236 observations in total.
The ABC-PD study contributed 91 observations from
91 individuals. The DeNoPa cohort had 123 individu-
als with 93 observations at baseline and 121 at the
second visit, giving 214 observations. The EPIPARK
cohort had 112 individuals contributing 111 observa-
tions at baseline. The Oxford Discovery cohort had
795 individuals, of which 778 had baseline observa-
tions, 468 with visit 2 and 193 with visit 3 data, giv-
ing 1,439 observations in total.)
The MoCA adjusted scores ranged from 8 to 30 in
our five cohorts with a median of 26 and an IQR
range of 23 to 28. The mean MoCA was 25.0 and the
SD 3.5. MMSE scores ranged from 13 to 30 with a
median of 28 and an IQR of 27 to 29. The mean was
27.6 and the SD 2.3. These results indicate that
MoCA may be better able to differentiate the range of
cognitive function and is less prone to ceiling effects.
Table 1 shows that the conversion using the method
proposed by van Steenoven and colleagues and our
own conversion are remarkably similar with the equiv-
alent MMSE only differing by 1 in 11 of 26 cases
(ignoring where the MoCA was 4 or lower). However,
it should be noted that we were both extrapolating to
MoCA scores below 8 (and below 10 in the van
Steenoven and colleagues article), so one must be cau-
tious at the very low end of the distribution.
Table 2 shows the difference (both within and
across cohorts) between the true and equivalent
MMSE for the van Steenoven and colleagues article
conversion and our own conversion. The median dif-
ference was 0 (IQR –1 to 1) for the van Steenoven
and colleagues article across all studies and the
median difference was also 0 within each study,
except for the MODEP cohort where the median dif-
ference was –1. However, even within the MODEP
cohort, the IQR was –1 to 0, still showing that at least
50% of the results are very close. The median differ-
ence was also 0 (IQR, –1 to 1) using our own internal
conversion across all the studies. The median
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difference was also 0 within each study, except for the
EPIPARK cohort where the median difference was 1.
Across all cohorts, the RMSE was remarkably simi-
lar comparing the van Steenoven conversion to our
own conversion, 1.88 compared to 1.84, respectively.
Comparing within the cohorts, the van Steenoven con-
version worked slightly better within the ABC-PD
study, the DeNoPa cohort, and the EPIPARK cohort
(lower RMSE and smaller mean differences), whereas
our own conversion worked slightly better within the
MODEP and Oxford Discovery cohorts.
The van Steenoven conversion demonstrated an
intraclass correlation coefficient of 0.66 (95% confi-
dence interval [CI]: 0.64–0.69) between the true and
equivalent MMSE. For the van Steenoven conversion,
11.1% of MMSE equivalent scores were more than 2
points higher than true MMSE, 83.8% were within 2
points, and 5.1% were more than 2 points lower. Our
own conversion showed an intraclass correlation coef-
ficient of 0.66 (95% CI: 0.64–0.68), with 8.1% of
MMSE equivalent scores were more than 2 points
higher than true MMSE, 83.2% were within 2 points,
and 8.7% were more than 2 points lower.
Discussion
Our replication of the analysis resulted in a very simi-
lar conversion table to the one in the van Steenoven
and colleagues, even though our sample is 10 times
larger (n 5 2,091, compared to n 5 197). Validation of
the conversion table from the van Steenoven and col-
leagues article shows that it has very good characteris-
tics, with 0 median and small IQR of the difference and
a RMSE, which is almost as good as our own internal
conversion across all cohorts. An internal validation
will almost always be better than an external valida-
tion, which further demonstrates the validity of the van
Steenoven conversion. These findings are similar to a
previously reported smaller validation study.5
Our sample had a wider range of MoCA and
MMSE performance than a previous publication (low-
est MoCA value 8 points, as compared to 17 points),
which greatly enhances the generalizability of this con-
version table. However, we still did not have any par-
ticipants with a MoCA less than 8. This limitation is
probably not of high clinical relevance given that it is
unusual to recruit subjects with such poor perform-
ance into research. For example, in the UK, ethical
committees would prohibit recruitment of subjects
who could not consent into research unless it was a
therapeutic trial that may have patient benefit.
TABLE 1. Conversion from MoCA to MMSE using the
equipercentile method with log-linear smoothing using our
datasets and compared to that from van Steenoven and
colleagues
MoCA Total
Adjusted
Equivalent MMSE Total
(From the van
Steenoven Article)
Equivalent MMSE Total
(Internal Data Conversion)
1 6 1
2 9 2
3 11 4
4 12 10
5 13 13
6 14 14
7 15 15
8 15 16
9 16 17
10 17 18
11 18 18
12 18 19
13 19 20
14 20 20
15 21 21
16 22 22
17 22 22
18 23 23
19 24 24
20 25 24
21 26 25
22 26 26
23 27 26
24 28 27
25 28 28
26 29 28
27 29 29
28 30 29
29 30 30
30 30 30
MoCA was adjusted for the years of education. Scores that are in the
shaded boxes are derived from extrapolated data.
TABLE 2. Validation of the MoCA to MMSE conversion using both the conversion from the van Steenoven and colleagues
article and our own internal conversion
van Steenoven Article Conversion Internal Conversion
Cohort N
MMSE Total–Equivalent MMSE:
Mean (SD); Median (IQR) RMSE
MMSE Total–Equivalent MMSE:
Mean (SD); Median (IQR) RMSE
MODEP6 236 –0.68 (1.45); 21 (21, 0) 1.60 –0.29 (1.51); 0 (21, 1) 1.54
ABC-PD 91 –0.13 (1.74); 0 (21, 1) 1.74 0.29 (1.80); 0 (21, 1) 1.82
DeNoPa7,8 214 0.08 (1.69); 0 (21, 1) 1.69 0.53 (1.72); 0 (21, 1) 1.80
EPIPARK9 111 0.32 (2.19); 0 (21, 2) 2.21 0.74 (2.14); 1 (21, 2) 2.25
Discovery10 1,439 –0.49 (1.86); 0 (22, 1) 1.92 –0.03 (1.85); 0 (21, 1) 1.85
All data 2,091 –0.39 (1.83); 0 (21, 1) 1.88 0.05 (1.84); 0 (21, 1) 1.84
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The equipercentile method has the strengths that it
can deal with nonlinearity within scales and that the
equated scores will always be within the range of pos-
sible scores. However, the method is limited because it
can lead to an irregular distribution of scores. An
alternative approach to combine data across studies
would be to internally standardize data using a Z-
score or a T-score12 method; however, these
approaches do not take into account the difference in
distributions or variability across the populations;
hence, we favor the former approach.
These results provide independent replication and
validation of a previous conversion table from MoCA
to MMSE. The closeness in scores using either conver-
sion table shows that this approach is useful in con-
verting MoCA scores to MMSE scores and enables
harmonization and meta-analysis across cohorts to
determine determinants of cognitive impairment or
decline in PD cohorts. This work needs to be extended
to other domains, such as olfaction, depression, and
so on, and to incorporate other methods, such as item
response theory, to enable researchers to apply cross-
scale conversions. This will greatly enhance the utility
of existing research data and facilitate greater collabo-
ration and shared analyses, leading to more robust
research findings.
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